A randomized, double-blind, placebo-controlled study to evaluate sildenafil, ambrisentan combination therapy in pulmonary hypertension, particularly of Eisenmenger syndrome

A randomized, double-blind, placebo-controlled study to evaluate sildenafil, ambrisentan combination therapy in pulmonary hypertension, particularly of Eisenmenger syndrome

Pulmonary arterial hypertension (PAH) - a complex and progressive disease that carries significant morbidity and mortality despite optimal medical treatment. Combination therapy for PAH can be more effective than monotherapy. The present randomized trial compared the safety and efficacy of sildenafi...

Full description

Bibliographic Details
Main Authors: Shaadab Mohammed, Rajesh Vijayvergiya, Samir Malhotra, Manoj Kumar Rohit
Format: Article
Language:English
Published: Elsevier 2021-09-01
Series:Indian Heart Journal
Subjects:
Ambrisentan
Combination therapy
Eisenmenger syndrome
Online Access:http://www.sciencedirect.com/science/article/pii/S0019483221001516
id doaj-ac5ca9d387d24ae787a7febf25b7d985
record_format Article
spelling doaj-ac5ca9d387d24ae787a7febf25b7d9852021-10-09T04:35:09ZengElsevierIndian Heart Journal0019-48322021-09-01735633636A randomized, double-blind, placebo-controlled study to evaluate sildenafil, ambrisentan combination therapy in pulmonary hypertension, particularly of Eisenmenger syndromeShaadab Mohammed0Rajesh Vijayvergiya1Samir Malhotra2Manoj Kumar Rohit3Department of Cardiology, Post Graduate Institute of Medical Education & Research, Chandigarh, 160012, IndiaDepartment of Cardiology, Post Graduate Institute of Medical Education & Research, Chandigarh, 160012, India; Corresponding author. Department of Cardiology, Advanced Cardiac Centre, Post Graduate Institute of Medical Education & Research, Sector 12, Chandigarh, 160 012, India.Department of Pharmacology, Post Graduate Institute of Medical Education & Research, Chandigarh, 160012, IndiaDepartment of Cardiology, Post Graduate Institute of Medical Education & Research, Chandigarh, 160012, IndiaPulmonary arterial hypertension (PAH) - a complex and progressive disease that carries significant morbidity and mortality despite optimal medical treatment. Combination therapy for PAH can be more effective than monotherapy. The present randomized trial compared the safety and efficacy of sildenafil ambrisentan combination therapy with sildenafil monotherapy. Twenty-two patients of Eisenmenger syndrome and five patients of idiopathic PAH were randomized to two arms. There was a significant improvement in NYHA functional class and mean pulmonary artery pressure, while an insignificant improving trend was observed for 6-min walk distance and oxygen saturation, following the 12 weeks of combination therapy. An upfront combination therapy was found to be safe and effective in the management of PAH patients.http://www.sciencedirect.com/science/article/pii/S0019483221001516AmbrisentanCombination therapyEisenmenger syndrome
collection DOAJ
language English
format Article
sources DOAJ
author Shaadab Mohammed
Rajesh Vijayvergiya
Samir Malhotra
Manoj Kumar Rohit
spellingShingle Shaadab Mohammed
Rajesh Vijayvergiya
Samir Malhotra
Manoj Kumar Rohit
A randomized, double-blind, placebo-controlled study to evaluate sildenafil, ambrisentan combination therapy in pulmonary hypertension, particularly of Eisenmenger syndrome
Indian Heart Journal
Ambrisentan
Combination therapy
Eisenmenger syndrome
author_facet Shaadab Mohammed
Rajesh Vijayvergiya
Samir Malhotra
Manoj Kumar Rohit
author_sort Shaadab Mohammed
title A randomized, double-blind, placebo-controlled study to evaluate sildenafil, ambrisentan combination therapy in pulmonary hypertension, particularly of Eisenmenger syndrome
title_short A randomized, double-blind, placebo-controlled study to evaluate sildenafil, ambrisentan combination therapy in pulmonary hypertension, particularly of Eisenmenger syndrome
title_full A randomized, double-blind, placebo-controlled study to evaluate sildenafil, ambrisentan combination therapy in pulmonary hypertension, particularly of Eisenmenger syndrome
title_fullStr A randomized, double-blind, placebo-controlled study to evaluate sildenafil, ambrisentan combination therapy in pulmonary hypertension, particularly of Eisenmenger syndrome
title_full_unstemmed A randomized, double-blind, placebo-controlled study to evaluate sildenafil, ambrisentan combination therapy in pulmonary hypertension, particularly of Eisenmenger syndrome
title_sort randomized, double-blind, placebo-controlled study to evaluate sildenafil, ambrisentan combination therapy in pulmonary hypertension, particularly of eisenmenger syndrome
publisher Elsevier
series Indian Heart Journal
issn 0019-4832
publishDate 2021-09-01
description Pulmonary arterial hypertension (PAH) - a complex and progressive disease that carries significant morbidity and mortality despite optimal medical treatment. Combination therapy for PAH can be more effective than monotherapy. The present randomized trial compared the safety and efficacy of sildenafil ambrisentan combination therapy with sildenafil monotherapy. Twenty-two patients of Eisenmenger syndrome and five patients of idiopathic PAH were randomized to two arms. There was a significant improvement in NYHA functional class and mean pulmonary artery pressure, while an insignificant improving trend was observed for 6-min walk distance and oxygen saturation, following the 12 weeks of combination therapy. An upfront combination therapy was found to be safe and effective in the management of PAH patients.
topic Ambrisentan
Combination therapy
Eisenmenger syndrome
url http://www.sciencedirect.com/science/article/pii/S0019483221001516
work_keys_str_mv AT shaadabmohammed arandomizeddoubleblindplacebocontrolledstudytoevaluatesildenafilambrisentancombinationtherapyinpulmonaryhypertensionparticularlyofeisenmengersyndrome
AT rajeshvijayvergiya arandomizeddoubleblindplacebocontrolledstudytoevaluatesildenafilambrisentancombinationtherapyinpulmonaryhypertensionparticularlyofeisenmengersyndrome
AT samirmalhotra arandomizeddoubleblindplacebocontrolledstudytoevaluatesildenafilambrisentancombinationtherapyinpulmonaryhypertensionparticularlyofeisenmengersyndrome
AT manojkumarrohit arandomizeddoubleblindplacebocontrolledstudytoevaluatesildenafilambrisentancombinationtherapyinpulmonaryhypertensionparticularlyofeisenmengersyndrome
AT shaadabmohammed randomizeddoubleblindplacebocontrolledstudytoevaluatesildenafilambrisentancombinationtherapyinpulmonaryhypertensionparticularlyofeisenmengersyndrome
AT rajeshvijayvergiya randomizeddoubleblindplacebocontrolledstudytoevaluatesildenafilambrisentancombinationtherapyinpulmonaryhypertensionparticularlyofeisenmengersyndrome
AT samirmalhotra randomizeddoubleblindplacebocontrolledstudytoevaluatesildenafilambrisentancombinationtherapyinpulmonaryhypertensionparticularlyofeisenmengersyndrome
AT manojkumarrohit randomizeddoubleblindplacebocontrolledstudytoevaluatesildenafilambrisentancombinationtherapyinpulmonaryhypertensionparticularlyofeisenmengersyndrome
_version_ 1716830783333728256

Similar Items